Managing Immune Thrombocytopenic Purpura in infants: is it time to think
We report 2 cases of infants with acute and persistent Immune
Thrombocytopenic Purpura (ITP) treated with Eltrombopag. Since ITP is
rare in infants, robust evidence about how to treat these patients is
not available. Both children underwent multiple lines of treatment
without success and were successfully managed with off-label use of
Eltrombopag. We did not observe any of the reported adverse effects of
the drug and complete remission was achieved in both cases. In one
child, we were able to discontinue treatment without any ITP relapse.
This is the first report of an off-label use of Eltrombopag in infants.